In the QUANTUM-R phase III study, which compared the second-generation FLT3 inhibitor quizartinib to salvage chemotherapy in R/R FLT3-ITD AML, quizartinib showed a survival benefit with an OS of 6.2 months compared to 4.7 in the control arm [181]. This evidence concerns the gene FLT3 and acute myeloid leukemia.